This article was downloaded by: [Michigan State University] On: 16 January 2015, At: 20:50 Publisher: Taylor & Francis Informa Ltd Registered in England and Wales Registered Number: 1072954 Registered office: Mortimer House, 37-41 Mortimer Street, London W1T 3JH, UK



Synthetic Communications: An International Journal for Rapid Communication of Synthetic Organic Chemistry

Publication details, including instructions for authors and subscription information: http://www.tandfonline.com/loi/lsyc20

Synthesis of 1, 2, 3, 9-Tetrahydro-7-bromo-6hydroxy-5-methoxypyrrolo-[2, 1-b]-quinazoline: A New Analog of Deoxyvasicine

Babatunde Ojo^a & Bejoy K. Chowdhury^b

^a Department of Medicinal and Biological Chemistry, Center for Drug Design and Development, College of Pharmacy, The University of Toledo, 2801 W. Bancroft Street, Toledo, OH, 43606-3390, USA

^b Department of Chemistry, School of Tropical Medicine, Calcutta, 700 073, W. Bengal, INDIA Published online: 23 Sep 2006.

To cite this article: Babatunde Ojo & Bejoy K. Chowdhury (1995) Synthesis of 1, 2, 3, 9-Tetrahydro-7-bromo-6-hydroxy-5-methoxypyrrolo-[2, 1-b]-quinazoline: A New Analog of Deoxyvasicine, Synthetic Communications: An International Journal for Rapid Communication of Synthetic Organic Chemistry, 25:4, 569-572, DOI: 10.1080/00397919508011391

To link to this article: http://dx.doi.org/10.1080/00397919508011391

PLEASE SCROLL DOWN FOR ARTICLE

Taylor & Francis makes every effort to ensure the accuracy of all the information (the "Content") contained in the publications on our platform.

However, Taylor & Francis, our agents, and our licensors make no representations or warranties whatsoever as to the accuracy, completeness, or suitability for any purpose of the Content. Any opinions and views expressed in this publication are the opinions and views of the authors, and are not the views of or endorsed by Taylor & Francis. The accuracy of the Content should not be relied upon and should be independently verified with primary sources of information. Taylor and Francis shall not be liable for any losses, actions, claims, proceedings, demands, costs, expenses, damages, and other liabilities whatsoever or howsoever caused arising directly or indirectly in connection with, in relation to or arising out of the use of the Content.

This article may be used for research, teaching, and private study purposes. Any substantial or systematic reproduction, redistribution, reselling, loan, sub-licensing, systematic supply, or distribution in any form to anyone is expressly forbidden. Terms & Conditions of access and use can be found at <u>http://www.tandfonline.com/page/terms-and-conditions</u>

SYNTHETIC COMMUNICATIONS, 25(4), 569-572 (1995)

SYNTHESIS OF 1, 2, 3, 9-TETRAHYDRO-7-BROMO-6-HYDROXY-5-METHOXYPYRROLO-[2, 1-<u>b</u>]-QUINAZOLINE: A NEW ANALOG OF DEOXYVASICINE

Babatunde Ojo* and Bejoy K. Chowdhury a


Department of Medicinal and Biological Chemistry, Center for Drug Design and Development, College of Pharmacy, The University of Toledo, 2801 W. Bancroft Street, Toledo, OH 43606-3390 USA. ^aDepartment of Chemistry, School of Tropical Medicine, Calcutta- 700 073, W. Bengal, INDIA

Abstract: A new deoxyvasicine analog (9) was synthesized by condensation of 2-amino-5-bromovanillin (6) with 4-aminobutyraldehyde (7) in phosphate buffer (pH 5.8) followed by hydrogenation of the resulting quinazolinium complex (8) at 65°C in presence of 5 % palladium-on-barium sulfate.

There has been a considerable interest in the synthesis¹⁻⁶ of vasicine and related analogs due to their extensive use in the traditional medicine⁷ as as a remedy for cold, cough, bronchitis, asthma and related cardiovascular disorders. Although the synthesis of vasicine and deoxyvasicine from ortho-aminobenzaldehyde and gamma-amino-alphahydroxybutyraldehyde diethyl acetal using the Schopf-Oechler scheme of vasicine synthesis has been well documented,⁴ there has been no literature report of the synthesis of 6-bromo-5-hydroxy-4-methoxydeoxyvasicine from vanillin. The bromo analog was synthesized to aid in establishing further structure-activity relationships within the quinazoline class of compounds. We now wish to report here the convenient synthesis of a new analog of deoxyvasicine from vanillin.

^{*} To whom correspondence should be addressed.

Vanillin (1) was converted through (5) to 2-amino-5-bromovanillin (6)^{8,9}. Liberation of 7 from the diethyl acetal in dilute aqueous solution at pH 2 at 80°C during 30 minutes followed by reaction⁴ with 6 at pH 5.8 (aqueous phosphate buffer) for 72 h at room temperature gave an orange solution of the 1, 2-dihydroquinazolinium cation (8).



SCHEME 1

REACTION CONDITIONS: a = Acetic anhydride, reflux, 3.5 h., b = HNO3, 2-6°C., c = KOH, MeOH., d = Br2, AcOH, Iodine (catalyst)., e = FeSO4, NH4OH., f = 4aminobutyraldehyde [7], pH 5.8 (aq. phosphate buffer), room temperature, 72 h., g = H2, 5 % Pd-on-barium sulfate, 65°C, 1.5 h.

Compound 8 was stirred vigorously with 5 % palladium-on-barium sulfate catalyst under a stream of hydrogen at 65° C for 1.5 h. The filtrate was basified with ammonia solution, then extracted (6 x 100 mL) with chloroform, the extracts were combined and dried (Na₂SO₄). Evaporation of solvents *in vacuo* and recrystallization from benzene and petroleum ether gave a gummy substance of 6-bromo-5-hydroxy-4-methoxydeoxyvasicine (9) (65 % overall yield) as the free base, then converted to the hydrochloride salt.

Experimental Section

1, 2, 3, 9-tetrahvdro-7-bromo-6-hvdroxy-5-methoxypyrrolo-[2, 1-b]-guinazoline

2-Amino-5-bromovanillin (0.5 g, 2.03 mmol) was dissolved with stirring and gentle heat in 90 % methanol (50 mL), then cooled to room temperature. 4-Aminobutyraldehyde diethyl acetal (0.4 g, 2.48 mmol) was dissolved in water (10 mL) and kept at 80°C at pH 2 for 30 minutes to liberate the free aldehyde. The pH of the solution of the aldehyde was adjusted to pH 5.5 with phosphate buffer and the solution was added to the solution of of 2-amino-5-bromovanillin and the pH of the mixture adjusted to pH 5.8 with aqueous phosphate buffer. The mixture was kept at room temperature for 72 h to give an orange solution of the quinazolinium complex. The orange solution was then stirred vigorously at 65°C in an atmosphere of hydrogen in the presence of 5 % palladium-on-barium sulfate (1.5 g) for 1.5 h. The catalyst was removed by filtration, the filtrate basified with ammonia and extracted with chloroform (100 mL x 6). The chloroform extracts were washed with water and dried (Na2SO4). Evaporation of solvents in vacuo and attempted crystallization (benzene and petroleum ether) gave a brown gummy substance. The hydrochloride salt was obtained by addition of 1.0 M HCl in ether to a benzene solution of the gummy substance to give a voluminous white precipitate, which was then filtered and recrystalized (benzene and petroleum ether) to give white crystals (0.3 g, 65 %) mp 215-217°C. ¹Hnmr (CDCl3): § 7.50 (1H, s, C7-H), 6.15 (1H, s, phenolic-H), 3.89 (3H, s, OCH3), 2.9-3.6 (2H, m, C1-H), 3.25 (2H, t, C3-H), 2.26 (2H, m, C2-H), 1.8-2.7 (2H, m, C8-H). IR (KBr): 3450-3300 (phenolic OH), 1650 (entire conjugative system), 1625-1460 (dihydroquinazoline ring system), 1632 (-C = N), 860 cm-1 (substituted benzene). UV (Absorption max., EtOH): 220, 276, 336 nm. Calc. for $C_{12}H_{13}N_{2}O_{2}Br.HCl: C$ 43.20, H 4.23, N 8.40, Br 23.95., Found: C 43.14, H 4.15, N 8.38, Br 23.89.

References

- 1. Spath, E., Kuffner, F. and Platzer, N. Ber., 1935, 68B, 699
- 2. Spath, E. and Platzer, N. Ber., 1936, 69, 255
- 3. Southwick, P.L. and Casanova, J. (Jr.,) J. Amer. Chem. Soc., 1958, 80, 1168
- 4. Leonard, N.J. and Martell (Jr.), M.J. Tett. Lett., 1960, (No. 25), 44-47

5. Sniekus, V.A. "Quinoline, quinazoline, acridone and related alkaloids". in *The Alkaloids*, J.W. Arrow Smith Ltd. Bristol, **1972**, *2*, 86

- 6. Johne, S., Jung, B., Groger, D. and Radeglia, R. J. Prakt. Chem., 1977, 319, 919
- 7. Chopra, R.N. and Ghosh, S. Indian J. Medical Research, 1925, 13, 205-212
- 8. Raiford, L.C. and Stoesser, W.C. J. Amer. Chem. Soc., 1928, 50, 2560
- 9. Benington, F.; Morin, R.D. and Clark (Jr.), L.C. J. Org. Chem., 1959, 24, 917

(Received in the USA 31 July 1994)